Search
Andexanet alfa
go.drugbank.com/drugs/DB14562ApprovedIt also prevents andexanet alfa from taking up space on phospholipid surface membranes, so that native FXa may bind and assemble the prothrominase complex [A35558]. … The amino acid residue modification from serine to alanine in the binding site of the catalytic domain allows more effective binding to FXa inhibitors and deters the andexanet alfa from converting prothrombin
Vonicog alfa
go.drugbank.com/drugs/DB12872ApprovedInvestigational[A264389] Vonicog alfa works to reduce bleeding events and bleeding times in patients with vWD, who have deficiencies in VWF.[A264389] … [A264444] Used to treat von Willebrand Disease (vWD), it mimics the biological actions of endogenous VWF,[L51274] which is a critical plasma glycoprotein involved in platelet adhesion and aggregation.
(S)-camphor
go.drugbank.com/drugs/DB11345ApprovedCamphor is a major active ingredient in over-the-counter balms and liniments supplied as topical analgesics by causing sensitization to heat and coolness to relieve minor muscle and joint pain [A33086]
Coccidioides immitis spherule
go.drugbank.com/drugs/DB11294ApprovedCoccidioides immitis spherule is a skin test antigen indicated to detect delayed-type hypersensitivity to Coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis.
Radium Ra 223 dichloride
go.drugbank.com/drugs/DB08913ApprovedInvestigationalAs a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. … It was first approved by the FDA in May 2013 and is currently marketed under the brand name Xofigo, which was formerly called Alpharadin.
Tildrakizumab
go.drugbank.com/drugs/DB14004ApprovedInvestigationalA study was performed on the pharmacokinetics of this drug on various ethnicities. The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects [A32257]. … Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis [A32255].
Vutrisiran
go.drugbank.com/drugs/DB16699ApprovedInvestigational[A249010] Vutrisiran was approved by the FDA in June 2022. … [A249010] TTR mutations lead to the formation of misfolded TTR proteins, which form amyloid fibrils that deposit in different types of tissues.
Belinostat
go.drugbank.com/drugs/DB05015ApprovedInvestigationalIt was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. … It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma.
Synonyms: (2E)-N-HYDROXY-3-(3-(PHENYLSULFAMOYL)PHENYL)PROP-2-ENAMIDE, N-Hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamideCiclopirox
go.drugbank.com/drugs/DB01188ApprovedInvestigationalIn particular, the agent is especially effective in treating Tinea versicolor. … Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of superficial mycoses.
Trimethobenzamide
go.drugbank.com/drugs/DB00662ApprovedInvestigationalIn dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate. … Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ).
Synonyms: N-[[4-(2-dimethylaminoethoxy)phenyl]methyl]-3,4,5-trimethoxybenzamide